Quality indicators for cervical cancer care in Japan

다국어 초록 (Multilingual Abstract)

Objective: Choice of hysterectomy and adjuvant treatment for International Federation of Gynecology and Obstetrics (FIGO) 2009 stage II endometrioid endometrial cancer (EEC) is still controversial. Aims of this study were to evaluate survival benefits and adverse effects of different hysterectomies with or without adjuvant radiotherapy (RT), and to identify prognostic factors.
Methods: The patients at 14 member hospitals of the Taiwanese Gynecologic Oncology Group from 1992 to 2013 were retrospectively investigated. Patients were divided into simple hysterectomy (SH) alone, SH with RT, radical hysterectomy (RH) alone, and RH with RT groups. Endpoints were recurrence-free survival (RFS), overall survival (OS), disease-specific survival (DSS), adverse effects and prognostic factors for survival.
Results: Total of 246 patients were enrolled. The 5-year RFS, OS, DSS and recurrence rates for the entire cohort were 89.5%, 94.3%, 96.2% and 10.2%, respectively. Patients receiving RH had more adverse effects including blood loss (p<0.001), recurrent urinary tract infections (p=0.013), and leg lymphedema (p=0.038). Age over 50-year (HR=9.2; 95% confidence interval [CI], 1.2–70.9) and grade 3 histology (HR=7.28; 95% CI, 1.45–36.6) were independent predictors of OS. Grade 3 histology was an independent predictor of RFS (HR=5.13; 95% CI, 1.38–19.1) and DSS (HR=5.97; 95% CI, 1.06–58.7). Patients receiving adjuvant RT had lower locoregional recurrence (p=0.046), but no impact on survival.
Conclusion: Different treatment modalities yield similar survival outcomes. Patients receiving SH with RT had lower locoregional recurrent with acceptable morbidity. Age and tumor grading remained significant predictors for survival among patients with FIGO 2009 stage II EEC.

다국어 초록 (Multilingual Abstract)

Objective: We aimed to propose a set of quality indicators (QIs) based on the clinical guidelines for cervical cancer treatment published by The Japan Society of Gynecologic Oncology, and to assess adherence to standard-of-care as an index of the quality of care for cervical cancer in Japan.
Methods: A panel of clinical experts devised the QIs using a modified Delphi method. Adherence to each QI was evaluated using data from a hospital-based cancer registry of patients diagnosed in 2013, and linked with insurance claims data, between October 1, 2012, and December 31, 2014. All patients who received first-line treatment at the participating facility were included. The QI scores were communicated to participating hospitals, and additional data about the reasons for non-adherence were collected.
Results: In total, 297 hospitals participated, and the care provided to 15,163 cervical cancer patients was examined using 10 measurable QIs. The adherence rate ranged from 50.0% for ‘cystoscope or proctoscope for stage IVA’ to 98.8% for ‘chemotherapy using platinum for stage IVB’. Despite the variation in care, hospitals reported clinically valid reasons for more than half of the non-adherent cases. Clinically valid reasons accounted for 75%, 90.9%, 73.4%, 44.5%, and 88.1% of presented non-adherent cases respectively.
Conclusion: Our study revealed variations in pattern of care as well as an adherence to standards-of-care across Japan. Further assessment of the causes of variation and non-adherence can help identify areas where improvements are needed in patient care.

참고문헌 (Reference)

1 Higashi T, "The national database of hospital-based cancer registries: a nationwide infrastructure to support evidence-based cancer care and cancer control policy in Japan" 44 : 2-8, 2014

2 Japan Society of Obstetrics and Gynecology, "The annual report of cervical cancer patients 2008" Japan Society of Obstetrics and Gynecology

3 Fitch K, "The RAND/UCLA appropriateness method user's manual" RAND

4 Whitney CW, "Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB–IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study" 17 : 1339-1348, 1999

5 Ryu SY, "Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer" 81 : e577-e581, 2011

6 Mabuchi S, "Radical hysterectomy with adjuvant radiotherapy versus definitive radiotherapy alone for FIGO stage IIB cervical cancer" 123 : 241-247, 2011

7 Yuji Ikeda, "Practice patterns of adjuvant therapy for intermediate/high recurrence risk cervical cancer patients in Japan" 대한부인종양학회 27 (27): 1-9, 2016

8 Morris M, "Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer" 340 : 1137-1143, 1999

9 Toita T, "Patterns of radiotherapy practice for patients with cervical cancer (1999–2001): patterns of care study in Japan" 70 : 788-794, 2008

10 Trimble EL, "Patterns of care for women with cervical cancer in the United States" 113 : 743-749, 2008

11 Ministry of Health, Labour and Welfare, "Overview of the “Cancer Control Act”" Ministry of Health, Labour and Welfare

12 National Cancer Center, "National database of hospital-based cancer registries: 5 year survival report 2008" National Cancer Center

13 "National Institutes of Health Consensus Development Conference statement on cervical cancer. April 1–3, 1996" 66 : 351-361, 1997

14 National Comprehensive Cancer Network, "NCCN clinical practice guidelines in oncology (cervical cancer)" National Comprehensive Cancer Network

15 Iwamoto M, "Monitoring and evaluating the quality of cancer care in Japan using administrative claims data" 107 : 68-75, 2016

16 Ebina Y, "Japan Society of Gynecologic Oncology guidelines 2011 for the treatment of uterine cervical cancer" 20 : 240-248, 2015

17 Fujikawa K, "High incidence of severe urologic complications following radiotherapy for cervical cancer in Japanese women" 80 : 21-23, 2001

18 International Agency for Research on Cancer, "GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012" International Agency for Research on Cancer

19 Nagase S, "Evidence-based guidelines for treatment of cervical cancer in Japan: Japan Society of Gynecologic Oncology (JSGO) 2007 edition" 15 : 117-124, 2010

20 Institute of Medicine Committee on Quality of Health Care in America, "Crossing the quality chasm: a new health system for the 21st century" National Academies Press (US) 2001

21 Rose PG, "Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer" 340 : 1144-1153, 1999

22 Matsuo K, "Comparison of adjuvant therapy for node-positive clinical stage IB–IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation" 141 : 1042-1051, 2017

23 Wataru Yamagami, "Clinical statistics of gynecologic cancers in Japan" 대한부인종양학회 28 (28): 1-13, 2017

24 Keys HM, "Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma" 340 : 1154-1161, 1999

25 Hori M, "Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project" 45 : 884-891, 2015

26 Carlson JA, "Are we appropriately selecting therapy for patients with cervical cancer? Longitudinal patterns-of-care analysis for stage IB–IIB cervical cancer" 90 : 786-793, 2014

27 Bristow RE, "Adherence to treatment guidelines for ovarian cancer as a measure of quality care" 121 : 1226-1234, 2013